Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2009

Open Access 01-12-2009 | Research

The expression and significance of P-glycoprotein, lung resistance protein and multidrug resistance-associated protein in gastric cancer

Authors: Wen-Qing Hu, Chun-Wei Peng, Yan Li

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2009

Login to get access

Abstract

Background

To detect the expression of multidrug resistance molecules P-glycoprotein (P-gp), Lung resistnce protein (LRP) and Multidrug resistance-associated protein (MRP) and analyze the relationship between them and the clinico-pathological features.

Methods

The expressions of P-gp, LRP and MRP in formalin-fixed paraffin-embedded tissue sections from 59 gastric cancer patients were determined by a labbelled Streptavidin-Peroxidase (SP) immunohistochemical technique, and the results were analyzed in correlation with clinicopathological data. None of these patients received chemotherapy prior to surgery.

Results

The positive rates of P-gp, LRP, MRP were 86.4%, 84.7% and 27.1%, respectively. The difference between the positive rate of P-gp and MRP was significant statistically, as well as the difference between the expression of MRP and LRP. No significant difference was observed between P-gp and LRP, but the positively correlation between the expression of P-gp and LRP had been found. No significant correlation between the expression of P-gp, LRP, MRP and the grade of differentiation were observed. The expression of P-gp was correlated with clinical stages positively (r = 0.742), but the difference with the expression of P-gp in different stages was not significant.

Conclusion

The expressions of P-gp, LRP and MRP in patients with gastric cancer without prior chemotherapy are high, indicating that innate drug resistance may exist in gastric cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, Malvezzi M, La Vecchia C: Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009, 125: 666-673. 10.1002/ijc.24290.CrossRef Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, Malvezzi M, La Vecchia C: Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009, 125: 666-673. 10.1002/ijc.24290.CrossRef
2.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRef Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRef
3.
go back to reference Qiu FM, Yu JK, Chen YD, Jin QF, Sui MH, Huang J: Mining novel biomarkers for prognosis of gastric cancer with serum proteomics. J Exp Clin Cancer Res. 2009, 28: 126-10.1186/1756-9966-28-126.CrossRef Qiu FM, Yu JK, Chen YD, Jin QF, Sui MH, Huang J: Mining novel biomarkers for prognosis of gastric cancer with serum proteomics. J Exp Clin Cancer Res. 2009, 28: 126-10.1186/1756-9966-28-126.CrossRef
4.
go back to reference Zhang WD, Miao SJ: Analysis on epidemic characteristics of cancer death rate in China. Chinese J Health Education. 2009, 25: 246-248. (In chinese with English abstract) Zhang WD, Miao SJ: Analysis on epidemic characteristics of cancer death rate in China. Chinese J Health Education. 2009, 25: 246-248. (In chinese with English abstract)
5.
go back to reference Cervantes A, Rosello S, Roda D, Rodriguez-Braun E: The treatment of advanced gastric cancer: current strategies and future perspectives. Ann Oncol. 2008, 19 (Suppl 5): v103-107. 10.1093/annonc/mdn321.CrossRef Cervantes A, Rosello S, Roda D, Rodriguez-Braun E: The treatment of advanced gastric cancer: current strategies and future perspectives. Ann Oncol. 2008, 19 (Suppl 5): v103-107. 10.1093/annonc/mdn321.CrossRef
6.
go back to reference Zhang D, Fan D: Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev Anticancer Ther. 2007, 7: 1369-1378. 10.1586/14737140.7.10.1369.CrossRef Zhang D, Fan D: Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev Anticancer Ther. 2007, 7: 1369-1378. 10.1586/14737140.7.10.1369.CrossRef
7.
go back to reference Truong CD, Feng W, Li W, Khoury T, Li Q, Alrawi S, Yu Y, Xie K, Yao J, Tan D: Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in U.S.A. J Exp Clin Cancer Res. 2009, 28: 14-10.1186/1756-9966-28-14.CrossRef Truong CD, Feng W, Li W, Khoury T, Li Q, Alrawi S, Yu Y, Xie K, Yao J, Tan D: Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in U.S.A. J Exp Clin Cancer Res. 2009, 28: 14-10.1186/1756-9966-28-14.CrossRef
8.
go back to reference Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007, 357: 1810-1820. 10.1056/NEJMoa072252.CrossRef Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007, 357: 1810-1820. 10.1056/NEJMoa072252.CrossRef
9.
go back to reference Peng CW, Li Y, Yang GL, Xiong B, Feng MH, Cheng FL: Postopreative recurrence in gastric cancer: analysis of 59 cases. Hepatogastroenterlogy. 2009 Peng CW, Li Y, Yang GL, Xiong B, Feng MH, Cheng FL: Postopreative recurrence in gastric cancer: analysis of 59 cases. Hepatogastroenterlogy. 2009
10.
go back to reference Kodera Y, Ito S, Mochizuki Y, Kondo K, Koshikawa K, Suzuki N, Kojima H, Kojima T, Matsui T, Takase T: A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). Eur J Surg Oncol. 2009, 35: 1158-1163.CrossRef Kodera Y, Ito S, Mochizuki Y, Kondo K, Koshikawa K, Suzuki N, Kojima H, Kojima T, Matsui T, Takase T: A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). Eur J Surg Oncol. 2009, 35: 1158-1163.CrossRef
11.
go back to reference Di Lauro L, Giacinti L, Arena MG, Sergi D, Fattoruso SI, Giannarelli D, Lopez M: Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma. J Exp Clin Cancer Res. 2009, 28: 34-10.1186/1756-9966-28-34.CrossRef Di Lauro L, Giacinti L, Arena MG, Sergi D, Fattoruso SI, Giannarelli D, Lopez M: Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma. J Exp Clin Cancer Res. 2009, 28: 34-10.1186/1756-9966-28-34.CrossRef
12.
go back to reference Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002, 2: 48-58. 10.1038/nrc706.CrossRef Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002, 2: 48-58. 10.1038/nrc706.CrossRef
13.
go back to reference Nobili S, Landini I, Giglioni B, Mini E: Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets. 2006, 7: 861-879. 10.2174/138945006777709593.CrossRef Nobili S, Landini I, Giglioni B, Mini E: Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets. 2006, 7: 861-879. 10.2174/138945006777709593.CrossRef
14.
go back to reference Saglam A, Hayran M, Uner AH: Immunohistochemical expression of multidrug resistance proteins in mature T/NK-cell lymphomas. APMIS. 2008, 116: 791-800. 10.1111/j.1600-0463.2008.00974.x.CrossRef Saglam A, Hayran M, Uner AH: Immunohistochemical expression of multidrug resistance proteins in mature T/NK-cell lymphomas. APMIS. 2008, 116: 791-800. 10.1111/j.1600-0463.2008.00974.x.CrossRef
15.
go back to reference Alexander D, Yamamoto T, Kato S, Kasai S: Histopathological assessment of multidrug resistance in gastric cancer: expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein. Surg Today. 1999, 29: 401-406. 10.1007/BF02483030.CrossRef Alexander D, Yamamoto T, Kato S, Kasai S: Histopathological assessment of multidrug resistance in gastric cancer: expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein. Surg Today. 1999, 29: 401-406. 10.1007/BF02483030.CrossRef
16.
go back to reference Fan K, Fan D, Cheng LF, Li C: Expression of multidrug resistance-related markers in gastric cancer. Anticancer Res. 2000, 20: 4809-4814. Fan K, Fan D, Cheng LF, Li C: Expression of multidrug resistance-related markers in gastric cancer. Anticancer Res. 2000, 20: 4809-4814.
17.
go back to reference Yu DQ, Yi YF: Expression and significance of MRP, GST-pi, Topo IIalpha, and LRP in gastric carcinoma. Ai Zheng. 2003, 22: 496-499. Yu DQ, Yi YF: Expression and significance of MRP, GST-pi, Topo IIalpha, and LRP in gastric carcinoma. Ai Zheng. 2003, 22: 496-499.
18.
go back to reference Zhang J, Ji J, Ji YB, Yuan F, Liu BY, Zhu ZG, Lin YZ: Antitumor effects of chemotherapeutic drugs on fresh human gastric cancer cells and their relationship to expression of P-glycoprotein and glutathione S transferase-pi. Ai Zheng. 2005, 24: 432-437. Zhang J, Ji J, Ji YB, Yuan F, Liu BY, Zhu ZG, Lin YZ: Antitumor effects of chemotherapeutic drugs on fresh human gastric cancer cells and their relationship to expression of P-glycoprotein and glutathione S transferase-pi. Ai Zheng. 2005, 24: 432-437.
19.
go back to reference Yin XD, Zhao JH, Zhang L, Wang LP, Lu LQ, Wang LW, Xie GH, Wu QZ, Wang SZ, Gu JP: Multi-slice CT contrast-enhanced presentations of advanced gastric cancer: associations with histo-differentiation and expression of p53 and P-glycoprotein. Chin Med J. 2008, 121: 2487-2491. Yin XD, Zhao JH, Zhang L, Wang LP, Lu LQ, Wang LW, Xie GH, Wu QZ, Wang SZ, Gu JP: Multi-slice CT contrast-enhanced presentations of advanced gastric cancer: associations with histo-differentiation and expression of p53 and P-glycoprotein. Chin Med J. 2008, 121: 2487-2491.
20.
go back to reference Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K: Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transterases, topoisomerase-II and Lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest. 2008, 26: 344-351. 10.1080/07357900701788072.CrossRef Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K: Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transterases, topoisomerase-II and Lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest. 2008, 26: 344-351. 10.1080/07357900701788072.CrossRef
21.
go back to reference Johnstone RW, Ruefli AA, Symth MJ: Multiple physiological functions for multidrug transporter P-glycoprotein?. Trends Biochem Sci. 2000, 25: 1-6. 10.1016/S0968-0004(99)01493-0.CrossRef Johnstone RW, Ruefli AA, Symth MJ: Multiple physiological functions for multidrug transporter P-glycoprotein?. Trends Biochem Sci. 2000, 25: 1-6. 10.1016/S0968-0004(99)01493-0.CrossRef
22.
go back to reference Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Konsgen D, Lage H, Noske A, Weichert W, Buckendahl AC: Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis. Histopathology. 2009, 54: 657-666. 10.1111/j.1365-2559.2009.03297.x.CrossRef Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Konsgen D, Lage H, Noske A, Weichert W, Buckendahl AC: Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis. Histopathology. 2009, 54: 657-666. 10.1111/j.1365-2559.2009.03297.x.CrossRef
23.
go back to reference Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM: P-glycoprotein: from genomics to mechanism. Oncogene. 2003, 22: 7468-7485. 10.1038/sj.onc.1206948.CrossRef Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM: P-glycoprotein: from genomics to mechanism. Oncogene. 2003, 22: 7468-7485. 10.1038/sj.onc.1206948.CrossRef
24.
go back to reference Steinbach D, Leqrand O: ABC transpoters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?. Leukemia. 2007, 21: 1172-1176. 10.1038/sj.leu.2404692.CrossRef Steinbach D, Leqrand O: ABC transpoters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?. Leukemia. 2007, 21: 1172-1176. 10.1038/sj.leu.2404692.CrossRef
25.
go back to reference Zhang Y, Qu X, Hu X, Yang X, Hou K, Teng Y, Zhang J, Sada K, Liu Y: Reversal of P-glycoprotein-meidiated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells. J Pathol. 2009, 218: 248-255. 10.1002/path.2533.CrossRef Zhang Y, Qu X, Hu X, Yang X, Hou K, Teng Y, Zhang J, Sada K, Liu Y: Reversal of P-glycoprotein-meidiated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells. J Pathol. 2009, 218: 248-255. 10.1002/path.2533.CrossRef
26.
go back to reference Han Z, Hong L, Han Y, Wu K, Han S, Shen H, Li C, Yao L, Qiao T, Fan D: Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. J Exp Clin Cancer Res. 2007, 26: 261-268. Han Z, Hong L, Han Y, Wu K, Han S, Shen H, Li C, Yao L, Qiao T, Fan D: Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. J Exp Clin Cancer Res. 2007, 26: 261-268.
27.
go back to reference Du J, Shi Y, Pan Y, Jin X, Lin C, Liu N, Han Q, Lu Y, Qiao T, Fan D: Regulation of multidrug resistance by ribosomal protein L6 in gastric cancer cells. Cancer BiolTher. 2005, 4: 242-247. 10.4161/cbt.4.2.1477. Du J, Shi Y, Pan Y, Jin X, Lin C, Liu N, Han Q, Lu Y, Qiao T, Fan D: Regulation of multidrug resistance by ribosomal protein L6 in gastric cancer cells. Cancer BiolTher. 2005, 4: 242-247. 10.4161/cbt.4.2.1477.
28.
go back to reference Robey RW, Shukla S, Finley E, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE: Inhibiton of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol. 2008, 75: 1302-1312. 10.1016/j.bcp.2007.12.001.CrossRef Robey RW, Shukla S, Finley E, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE: Inhibiton of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol. 2008, 75: 1302-1312. 10.1016/j.bcp.2007.12.001.CrossRef
29.
go back to reference Lordick F, Jager D: Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancer. Gastrointest Cancer Res. 2008, 2: 187-197. Lordick F, Jager D: Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancer. Gastrointest Cancer Res. 2008, 2: 187-197.
30.
go back to reference Ullah MF: Cancer Multidrug Resistance (MDR): A Major Impediment to Effective Chemotherapy. Asian Pacific J Cancer Prev. 2008, 9: 1-6. Ullah MF: Cancer Multidrug Resistance (MDR): A Major Impediment to Effective Chemotherapy. Asian Pacific J Cancer Prev. 2008, 9: 1-6.
Metadata
Title
The expression and significance of P-glycoprotein, lung resistance protein and multidrug resistance-associated protein in gastric cancer
Authors
Wen-Qing Hu
Chun-Wei Peng
Yan Li
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2009
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-28-144

Other articles of this Issue 1/2009

Journal of Experimental & Clinical Cancer Research 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine